pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Elevidys · news · pharmadog
← back to Elevidys
News mentioning Elevidys
13
stories
3d
Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027
biospace
Aug 18, 26
Assessing shared failures with AI is key to cell and gene therapy’s evolution
biospace
Aug 6, 26
Sarepta pushes back Elevidys timeline; Emergent lays off 90 staffers
endpoints
Jul 31, 26
Capricor CEO won’t rule out legal action against FDA after negative adcomm
biospace
Jul 27, 26
Sarepta names former AbbVie R&D exec Michael Severino as next CEO
biospace
Jul 27, 26
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO
biopharma dive
Jul 27, 26
FDA has recommitted to adcomms—but to what end?
biospace
Jul 21, 26
Dyne gets early 2027 decision date for Duchenne therapy, analysts expect ‘smooth’ review
biospace
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 18, 26
Pfizer CFO to step down; Denali sells a regulatory fast-pass
biopharma dive
May 14, 26
With new data, Regenxbio to seek FDA approval of Duchenne gene therapy
biopharma dive
May 14, 26
STAT+: Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission
stat
May 7, 26
Sarepta tumbles as its gene therapy sales decline further
biopharma dive
